Moderna, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Moderna, Inc. stock analysis MRNA overview
Bullish +75

Moderna Stock Surges 16% Following Global Patent Litigation Settlement - TIKR.com

📈 Moderna stock jumped 16% following a $950 million patent settlement with Arbutus Biopharma and Genevant Sciences.

💰 The deal includes no future royalties, providing immediate cash relief and clearing the path for new products like mNexspike.

⚖️ Analysts view the outcome as 'better than feared,' avoiding a worst-case liability scenario that could have reached $5 billion.

🛡️ A potential additional $1.3 billion liability exists only if Moderna loses a separate Federal Circuit appeal on government contractor immunity.

💵 Moderna expects to finish the year with $4.5–$5 billion in cash, significantly bolstering its balance sheet.

📉 Costs were cut by $2.2 billion year-over-year while 2025 revenue reached $1.9 billion.

🚀 The company guides for up to 10% revenue growth in 2026 driven by international expansion and mNexspike sales.

🧬 A key upcoming catalyst is Phase 3 adjuvant melanoma data from the partnership with Merck expected later this year.

📅 The settlement covers all worldwide litigation tied to Spikevax and mResvia, removing major legal uncertainty.

Bullish Signals
  • Moderna secured a $950 million one-time payment that strengthens its cash position without incurring future royalty obligations.
  • The settlement removes a massive legal overhang, with analysts noting the company 'dodged a bullet' compared to feared $5 billion liabilities.
  • Costs were reduced by $2.2 billion year-over-year while revenue grew to $1.9 billion in 2025, indicating improved operational efficiency.
  • The legal resolution clears the path for future product launches including mNexspike and mCombriax, supporting long-term growth.
  • Management provided a concrete cash runway of $4.5–$5 billion by year-end, giving investors confidence in financial stability.
  • The company is guiding for up to 10% revenue growth in 2026 driven by international expansion and second-year mNexspike sales.
  • A major catalyst remains the Phase 3 adjuvant melanoma data from the Merck partnership, which could validate the cancer vaccine pipeline.
Risk Factors
  • Moderna faces a potential additional liability of $1.3 billion within 90 days if it loses a separate Federal Circuit appeal regarding government contractor immunity.
  • The company still has significant legal history with patent disputes that have caused stock volatility throughout the year.
Full Analysis
Moderna (MRNA) shares surged 16% on March 4 after the company reached a settlement with Arbutus Biopharma and Genevant Sciences regarding patents for its COVID vaccines. The agreement includes a one-time payment of $950 million to Moderna, with no future royalties required. This resolution removes a significant legal overhang that had weighed on investor sentiment for years. Analysts expressed relief at the outcome, noting that the settlement was far better than the feared worst-case scenario which could have involved up to $5 billion in liability. While there remains a potential additional exposure of $1.3 billion if Moderna loses a separate Federal Circuit appeal regarding government contractor immunity, this risk is viewed as manageable compared to the previous uncertainty. The settlement clears the path for future product launches, including mNexspike and mCombriax, and provides Moderna with a concrete cash position expected between $4.5 billion and $5 billion by year-end. Underlying fundamentals are also strengthening, with 2025 revenue reaching $1.9 billion and costs reduced by $2.2 billion year-over-year. Looking ahead, the company is guided for up to 10% revenue growth in 2026 driven by international expansion and continued sales of mNexspike. A major upcoming catalyst is the Phase 3 adjuvant melanoma data from Moderna's cancer vaccine partnership with Merck, which could further validate the company's pipeline potential.